Gut Microbiota in Immuno-Oncology: A Practical Guide for Medical Oncologists With a Focus on Antibiotics Stewardship Bispecific antibodies (bsAbs) have emerged as a novel class of therapeutics, ...

Investors in Regeneron Pharmaceuticals, Inc. (Symbol: REGN) saw new options become available today, for the May 30th expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...

India supplies nearly 50% of U.S. generic drugs; tariffs could disrupt $13 billion in exports. A Section 232 probe may delay pharma tariffs until late 2025 or beyond. Markets are messy—but the ...

As you can see from the chart above the percentage of shares that are sold short for Regeneron Pharmaceuticals has grown since its last report. This does not mean that the stock is going to fall ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and ...

Atlas Capital Advisors didn’t just up their Regeneron stake—they launched it into orbit with a 5,620.3% increase, now holding $6 million in shares. Other institutional investors also shuffled their ...

A drugmaker with one of the world's top-selling drugs Regeneron (NASDAQ: REGN) is a well-established biotech company that generates consistent revenue and profits. However, the drugmaker ...

Moving in the opposite direction was Sanofi and Regeneron’s Dupixent, which dropped three spots to No. 7 in March as TV ad spending fell from $22.4 million to just under $21 million. A pair of ...

One catalyst could lead to major gains for Regeneron. It is in a legal battle with Amgen over the legality of the latter's Eylea biosimilar. If Regeneron wins the case, its shares will rocket.

Pamalican Asset Management just snagged 6,900 shares of Regeneron Pharmaceuticals, making the biotech giant its 16th largest holding. This $4.9 million investment joins a stampede of institutional ...